Expert Insights: Expert Tumor Board to Address Challenging Cases of Relapsed/Refractory Aggressive and Indolent Lymphomas
Release Date: September 24, 2021
Expiration Date:September 23, 2022
Watch the experts who are actively engaged in the care of patients with lymphoma as they reinforce key points and highlight the most clinically relevant data presented at the August 9th satellite symposia during the 2021 Pan Pacific Lymphoma Conference.
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma.
After participating in this activity, participants should be better able to:
- Assess current and emerging approaches to the treatment of patients with aggressive B-cell lymphoma, and optimal patient management strategies
- Evaluate clinical trial data of both approved and novel agents and regimens being investigated in patients with indolent lymphoma
- Discuss approaches to the care of patients with rare lymphoma subtypes, including Burkitt lymphoma and peripheral T-cell lymphoma
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Nebraska Medical Center designates this activity for up to .25 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must:
1) read the educational objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Faculty and Planning Committee Disclosures
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
Matthew Lunning, DO, FACP (Moderator)
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Ranjana Advani, MD
Saul A. Rosenberg Professor of Lymphoma
Physician Leader, Lymphoma Critical Care Program
Stanford Cancer Institute
Palo Alto, California
Matthew Lunning, DO, FACP
Consultant: Acrotech Biopharma; AstraZeneca/Acerta; Beigene; Bristol Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen/ Pharmacyclics; Karyopharm; Kite; Legend Pharmaceuticals; MorphoSys; Myeloid Therapeutics; Spectrum; TG Therapeutics; Verastem
Research Grant Support: Bristol-Myers Squibb; Curis
Advisory Board: Celgene
Ranjana Advani, MD
Consultant: ADC Therapeutics; BeiGene; Daiichi Sankyo; Incyte Corp.; Karyopharm; Kura; Portola Pharmaceuticals; Sanofi
Research Funding: Bristol Myers Squibb; Celgene; Kura; Merck; Roche/ Genentech; Seattle Genetics; Takeda/Millennium
Advisory Board: Roche/Genentech
The following planning committee members have nothing to disclose:
UNMC: Heidi Keeler, PhD, RN; Renee Paulin, MSN, RN. CWOCN; Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Kraig Steubing; Dru Dace, PhD
This activity is supported by educational grants from Daiichi-Sankyo, Inc., Genentech, a member of the Roche Group, Incyte Corporation, MorphoSys, and TG Therapeutics, Inc.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.